• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Receptors
You are here: Product Lines > Signal Transduction > Receptors
 
Toolbar - View Selection
 
 Items 400-500 of 1015 Page 5 of 11 Select Page: << 1 2 3 4 5 6 7 8 9 10  >>  
ALX-550-411 Revised 11-Apr-07
LY2183240
Add to Clipboard
SYNONYMS 5-Biphenyl-4-ylmethyltetrazole-1-carboxylic acid dimethylamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Anandamide Uptake Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-550-411-M010   10 mg 60.00 USD Add To Cart
ALX-550-411-M050   50 mg 240.00 USD Add To Cart
Product Specification
FORMULA: C17H17N5O
MW: 307.4
CAS NUMBER: 874902-19-9
PURITY: ≥98% (TLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO or dimethyl formamide.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C

Product Description
Initially described as potent, competitive small molecule inhibitor of anandamide uptake. Has recently been shown to inhibit fatty acid amide hydrolase (FAAH) and several additional serine hydrolases.
Product Specific Literature References
Identification of a high-affinity binding site involved in the transport of endocannabinoids: S.A. Moore, et al.; PNAS 102, 17852 (2005) Abstract; Full Text
Toward an anandamide transporter: R. Mechoulam and D.G. Deutsch; PNAS 102, 17541 (2005) Abstract
The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases: J.P. Alexander and B.F. Cravatt; JACS 128, 9699 (2006) Abstract
Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors: A.K. Dickason-Chesterfield, et al.; Cell. Mol. Neurobiol. 26, 407 (2006) Abstract
Further Categories Containing This Product:
Fatty Acid Amide Hydrolase [FAAH] / Related Products
 
 
ALX-301-002 Revised 09-Dec-04
Lyso-PAF (C16)
Add to Clipboard
SYNONYMS 1-O-Hexadecyl-sn-glycero-3-phosphocholine
PRODUCT LINE Inflammation
PRODUCT CATEGORY Platelet Activating Factors [PAF] & Receptors / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-301-002-M001   1 mg 15.00 USD Add To Cart
ALX-301-002-M005   5 mg 45.00 USD Add To Cart
ALX-301-002-M025   25 mg 135.00 USD Add To Cart
ALX-301-002-M100   100 mg 280.00 USD Add To Cart
Product Specification
FORMULA: C24H52NO6P
MW: 481.7
CAS NUMBER: 52691-62-0
SOURCE/HOST: Synthetic.
PURITY: ≥98%
SOLUBILITY: Soluble in chloroform, methanol or ethanol. Soluble in water after sonification for 1 minute at 40°C.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Slightly hygroscopic.

Further Categories Containing This Product:
Phospholipids / Related Products
 
 
ALX-301-004 Revised 09-Dec-04
Lyso-PAF (C18)
Add to Clipboard
SYNONYMS 1-O-Octadecyl-sn-glycero-3-phosphocholine
PRODUCT LINE Inflammation
PRODUCT CATEGORY Platelet Activating Factors [PAF] & Receptors / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-301-004-M001   1 mg 15.00 USD Add To Cart
ALX-301-004-M005   5 mg 45.00 USD Add To Cart
ALX-301-004-M025   25 mg 135.00 USD Add To Cart
Product Specification
FORMULA: C26H56NO6P
MW: 509.7
CAS NUMBER: 74430-89-0
SOURCE/HOST: Sythetic.
PURITY: ≥98%
SOLUBILITY: Soluble in chloroform, methanol or 100% ethanol. Soluble in water after sonification for 1 minute at 40°C.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Slightly hygroscopic.

Further Categories Containing This Product:
Phospholipids / Related Products
 
 
ALX-162-034 Revised 03-Jul-08 New product
MALP-2 (BULK)
Add to Clipboard
SYNONYMS Macrophage-activating Lipopeptide-2
S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-GNNDESNISFKEK]
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-034-C500   500 µg 1'250.00 USD Add To Cart
Product Specification
FORMULA: C99H167N19O30S
MW: 2135.2
SOURCE/HOST: Synthetic.
CONCENTRATION: 1mg/ml
PURITY DETAIL: HPLC purified
FORMULATION: Liquid. Pyrogen-free, sterile solution in 33% (v/v) 2-propanol/water.
BIOLOGICAL ACTIVITY: Stimulates macrophages, monocytes and other TLR2 and TLR6 expressing cells in vitro at pg/ml concentrations (e.g. mouse macrophages: 50pg/ml; fibroblasts: 2ng/ml) to release various mediators. Human monocytes require about 10-100x higher concentrations for optimal cytokine or chemokine release than mouse PECS (see [12]). In vivo active at 0.5-5μg (e.g 0.5μg/20g mouse). The presence of 50mM octyl glucoside as carrier gives rise to a higher activity.
SHIPPING: SHIPPED ON DRY ICE
SHORT TERM STORAGE: -20°C
LONG TERM STORAGE: -80°C
USE/STABILITY: Stable for at least 3 years when stored at -20°C. This stock solution is stable for many months when kept in the refrigerator. MALP-2 solutions in the presene of carrier (50mM octyl glucoside, see Background/Technical Information below) are stable at +4°C at least 6 weeks. Some (10%) decrease of activity may occur shortly after transfer into new vessels. This is not due to decomposition but to adsorption (see below). Storage at room temperature for short periods of time does not influence bioactivity. When deep-frozen, MALP-2 does not loose activity within years.
HANDLING: Avoid freeze/thaw cycles. Avoid accidental injection, extreme care should be taken with hypodermic syringes. Avoid inhalation and prevent this compound from entering the bloodstream.
HAZARD: TOXIC.
Product Description
MALP-2 was originally isolated from Mycoplasma fermentans. This MALP-2 corresponds to the originally isolated isomer, which expresses potent endotoxin-like activity and approaches in certain experimental systems the toxicity of LPS. For description of the stereochemistry of MALP-2 (see [7]). MALP-2 signalling, unlike that of LPS, is not transduced via TLR4, but is induced via TLR2 and TLR6 signalling.
For more information about MALP-2 see www.malp-research.de.
New BULK size (500μg) of biologically active, pyrogen-free and sterile MALP-2 for in vitro and animal in vivo studies.
Product Specific Literature References
[1] Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6: P.F. Muhlradt and M. Frisch; Infect. Immun. 62, 3801 (1994) Abstract
[2] Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration: P.F. Mühlradt, et al.; J. Exp. Med. 185, 1951 (1997) Abstract; Full Text
[3] MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?: C. Galanos, et al.; J. Endotox. Res. 6, 471 (2000) Abstract
[4] Discrimination of bacterial lipoproteins by Toll-like receptor 6: O. Takeuchi, et al.; Int. Immunol. 13, 933 (2001) Abstract
[5] In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application: A. Luhrmann, et al.; Infect. Immun. 70, 3785 (2002) Abstract; Full Text
[6] The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant: F. Rharbaoui, et al.; Eur. J. Immunol. 32, 2857 (2002) Abstract
[7] Differential recognition of structural details of bacterial lipopeptides by toll-like receptors: M. Morr, et al.; Eur. J. Immunol. 32, 3337 (2002) Abstract
[8] CD14 is required for MyD88-independent LPS signaling: Z. Jiang, et al.; Nat. Immunol. 6, 565 (2005) Abstract
[9] The tumor suppressor CYLD Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via Negative Cross-talk with TRAF6 and TRAF7: H. Yoshida, et al.; J. Biol. Chem. 280, 41111 (2005) Abstract; Full Text
[10] IRF-7 is the master regulator of type-I interferon-dependent immune responses: K. Honda, et al.; Nature 434, 772 (2005) Abstract
[11] The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies: N. Satta, et al.; Blood 109, 1507 (2007) Abstract
[12] Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2: A. Kaufmann, et al.; Infect. Immun. 67, 6303 (1999) Abstract; Full Text
General Information
BACKGROUND/TECHNICAL INFORMATION MALP-2 sticks avidly to glass or plastic. Since it is active at very low concentrations, i.e. at high dilutions, these low amounts of material tend to become adsorbed to pipette tips and plastic or glass containers. To avoid this, prepare several dilution steps of the MALP-2 stock solution with medium containing 5% autologous serum or buffers with 2% HSA. The presence of 50mM octyl glucoside in the first dilution step is often beneficial and gives rise to higher activity. Avoid small volumes in large vessels. Do not filter.
Because of the ester-bound fatty acids, MALP-2 is sensitive to alkali or acid. The medium should be preconditioned in the CO2 incubator in order to ensure that the pH does not become alkaline. Add cells in preconditioned medium as soon as possible and incubate.
MANUFACTURER Licensed from GBF Braunschweig, Germany.
General Literature References
Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages: T. Into, et al.; Infect. Immun. 70, 3586 (2002) Abstract; Full Text
Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans: K.L. Davis & K.S. Wise; Infect. Immun. 70, 1129 (2002) Abstract; Full Text
Related Products
Further Categories Containing This Product:
Peptides
 
 
ALX-162-027 Revised 30-Jun-08
MALP-2
Add to Clipboard
SYNONYMS Macrophage-activating Lipopeptide-2
S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-GNNDESNISFKEK]
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-027-C050   50 µg 310.00 USD Add To Cart
Product Specification
FORMULA: C99H167N19O30S
MW: 2135.2
SOURCE/HOST: Synthetic.
QUANTITY: 1x107units.
CONCENTRATION: 0.1mg/ml
FORMULATION: Liquid. Sterile solution in PBS containing 2.5% (v/v) 2-propanol, 25mM n-octyl-β-D-glucopyranoside and 1% (wt/v) human serum albumin.
ACTIVITY: Specific activity is ~2x108units/mg. One unit is defined as the dilution giving half maximal release of nitric oxide from C3H/HeJ mouse peritoneal exudate cells in the standard assay (see [1]).
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: -20°C
LONG TERM STORAGE: -80°C
USE/STABILITY: Stable for at least 2 years when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. Avoid accidental injection, extreme care should be taken with hypodermic syringes. Avoid inhalation and prevent this compound from entering the bloodstream.
HAZARD: TOXIC.
Product Description
MALP-2 was originally isolated from Mycoplasma fermentans. This MALP-2 corresponds to the originally isolated isomer, which expresses potent endotoxin-like activity and approaches in certain experimental systems the toxicity of LPS. For description of the stereochemistry of MALP-2 (see [7]). MALP-2 signalling, unlike that of LPS, is not transduced via TLR4, but is induced via TLR2 and TLR6 signalling.
For more information about MALP-2 see www.malp-research.de.
Product Specific Literature References
[1] Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6: P.F. Muhlradt and M. Frisch; Infect. Immun. 62, 3801 (1994) Abstract
[2] Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration: P.F. Mühlradt, et al.; J. Exp. Med. 185, 1951 (1997) Abstract; Full Text
[3] MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?: C. Galanos, et al.; J. Endotox. Res. 6, 471 (2000) Abstract
[4] Discrimination of bacterial lipoproteins by Toll-like receptor 6: O. Takeuchi, et al.; Int. Immunol. 13, 933 (2001) Abstract
[5] In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application: A. Luhrmann, et al.; Infect. Immun. 70, 3785 (2002) Abstract; Full Text
[6] The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant: F. Rharbaoui, et al.; Eur. J. Immunol. 32, 2857 (2002) Abstract
[7] Differential recognition of structural details of bacterial lipopeptides by toll-like receptors: M. Morr, et al.; Eur. J. Immunol. 32, 3337 (2002) Abstract
[8] CD14 is required for MyD88-independent LPS signaling: Z. Jiang, et al.; Nat. Immunol. 6, 565 (2005) Abstract
[9] The tumor suppressor CYLD Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via Negative Cross-talk with TRAF6 and TRAF7: H. Yoshida, et al.; J. Biol. Chem. 280, 41111 (2005) Abstract; Full Text
[10] IRF-7 is the master regulator of type-I interferon-dependent immune responses: K. Honda, et al.; Nature 434, 772 (2005) Abstract
[11] The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies: N. Satta, et al.; Blood 109, 1507 (2007) Abstract
[12] Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2: A. Kaufmann, et al.; Infect. Immun. 67, 6303 (1999) Abstract; Full Text
General Information
BACKGROUND/TECHNICAL INFORMATION MALP-2 sticks avidly to glass or plastic. Since it is active at very low concentrations, i.e. at high dilutions, these low amounts of material tend to become adsorbed to pipette tips and plastic or glass containers. To avoid this, prepare several dilution steps of the MALP-2 stock solution with medium containing 5% autologous serum or buffers with 2% HSA. The presence of 50mM octyl glucoside in the first dilution step is often beneficial and gives rise to higher activity. Avoid small volumes in large vessels. Do not filter.
Because of the ester-bound fatty acids, MALP-2 is sensitive to alkali or acid. The medium should be preconditioned in the CO2 incubator in order to ensure that the pH does not become alkaline. Add cells in preconditioned medium as soon as possible and incubate.
MANUFACTURER Licensed from GBF Braunschweig, Germany.
General Literature References
Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages: T. Into, et al.; Infect. Immun. 70, 3586 (2002) Abstract; Full Text
Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans: K.L. Davis & K.S. Wise; Infect. Immun. 70, 1129 (2002) Abstract; Full Text
Related Products
Further Categories Containing This Product:
Peptides
 
 
ALX-550-118 Revised 28-Jan-05
MAP4
Add to Clipboard
SYNONYMS (S)-2-Amino-2-methyl-4-phosphonobutanoic acid
α-Methyl-AP4
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Glutamate Receptors (Metabotropic) / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-550-118-M005   5 mg 75.00 USD Add To Cart
Product Specification
FORMULA: C5H12NO5P
MW: 197.1
CAS NUMBER: 157381-42-5
PURITY: ≥96%
APPEARANCE: White powder.
SOLUBILITY: Soluble in dilute aqueous base.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C

Product Description
Selective agonist for group III mGluRs.
Product Specific Literature References
Actions of two new antagonists showing selectivity for different sub-types of metabotropic glutamate receptor in the neonatal rat spinal cord: D.E. Jane, et al.; Br. J. Pharmacol. 112, 809 (1994) Abstract
Phenylglycine derivatives as antagonists of metabotropic glutamate receptors: J. Watkins and G. Collingridge; TIPS 15, 333 (1994), (Review) Abstract
Antagonism of the synaptic depressant actions of L-AP4 in the lateral perforant path by MAP4: T.J. Bushell, et al.; Neuropharmacology 34, 239 (1995) Abstract
Pharmacological characterization of MCCG and MAP4 at the mGluR1b, mGluR2 and mGluR4a human metabotropic glutamate receptor subtypes: T. Knöpfel, et al.; Neuropharmacology 34, 1099 (1995) Abstract
Distinct presynaptic metabotropic receptors for L-AP4 and CCG1 on GABAergic terminals: pharmacological evidence using novel alpha-methyl derivative mGluR antagonists, MAP4 and MCCG, in the rat thalamu: T.E. Salt & S.A. Eaton; Neuroscience 65, 5 (1995) Abstract
Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists: J. Gomeza, et al.; Mol. Pharmacol. 50, 923 (1996) Abstract
Agonists of cyclic AMP-coupled metabotropic glutamate receptors in adult rat cortical slices: M.C. Kemp, et al.; Eur. J. Pharmacol. 309, 79 (1996) Abstract
Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes: N. Sekiyama, et al.; Br. J. Pharmacol. 117, 1493 (1996) Abstract
Neuroprotective effects of group III mGluR in traumatic neuronal injury: A.I. Faden, et al.; J. Neurotrauma 14, 885 (1997) Abstract
 
 
ALX-550-075 Revised 10-Feb-05
(S)-MCPG
Add to Clipboard
SYNONYMS (S)-α-Methyl-4-carboxyphenylglycine
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Glutamate Receptors (Metabotropic) / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-550-075-M005   5 mg 80.00 USD Add To Cart
ALX-550-075-M025   25 mg 320.00 USD Add To Cart
Product Specification
FORMULA: C10H11NO4
MW: 209.2
CAS NUMBER: 150145-89-4
PURITY: ≥97%
APPEARANCE: White solid.
SOLUBILITY: Soluble in dilute aqueous base.
SHIPPING: AMBIENT
LONG TERM STORAGE: +20°C
HANDLING: Protect from light.

Product Description
Active isomer of (RS)-MCPG (Prod. No. ALX-550-054). Non selective group I/group II mGluR antagonist.
Product Specific Literature References
Stereospecific antagonism by (+)-alpha-methyl-4-carboxyphenylglycine (MCPG) of (1S,3R)-ACPD-induced effects in neonatal rat motoneurones and rat thalamic neurones: D.E. Jane, et al.; Neuropharmacology 32, 725 (1993) Abstract
Antagonism of presynaptically mediated depressant responses and cyclic AMP-coupled metabotropic glutamate receptors: M. Kemp, et al.; Eur. J. Pharmacol. 266, 187 (1994) Abstract
Phenylglycine derivatives as antagonists of metabotropic glutamate receptors: J. Watkins & G. Collingridge; TIPS 15, 333 (1994), (Review) Abstract
Pharmacological analysis of 4-carboxyphenylglycine derivatives: comparison of effects on mGluR1 alpha and mGluR5a subtypes: A.E. Kingston, et al.; Neuropharmacology 34, 887 (1995) Abstract
Agonists and antagonists for metabotropic glutamate receptors: P.L. Ornstein, et al.; Curr. Pharm. Design 1, 355 (1995), (Review)
Effects of the metabotropic glutamate receptor antagonist MCPG on spatial and context-specific learning: F. Bordi, et al.; Neuropharmacology 35, 1557 (1996) Abstract
Stereoselective Synthesis of (S)-(+)-alpha-M4CPG, a Selective Antagonist of Metabotropic Glutamate Receptors: M. Dawei & T. Hongqi; Tetrahydron Assym. 7, 1567 (1996)
Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes: N. Sekiyama, et al.; Br. J. Pharmacol. 117, 1493 (1996) Abstract
(R,S)-alpha-methyl-4-carboxyphenylglycine (MCPG) fails to block long-term potentiation under urethane anaesthesia in vivo: S.J. Martin & R.G. Morris; Neuropharmacology 36, 1339 (1997) Abstract
Absolute configuration of (+)-alpha-methyl-4-carboxyphenylglycine (MCPG), a metabotropic glutamate receptor antagonist: C. Wilson, et al.; Acta. Crystallogr. C 53 ( Pt 7), 909 (1997) Abstract
Inhibition of group I metabotropic glutamate receptors blocks spatial learning in rats: D. Balschun & W. Wetzel; Neurosci. Lett. 249, 41 (1998) Abstract
(+)-MCPG blocks induction of LTP in CA1 of rat hippocampus via agonist action at an mGluR group II receptor: N.A. Breakwell, et al.; J. Neurophysiol. 79, 1270 (1998) Abstract
The metabotropic glutamate receptor antagonist (RS)-MCPG produces hyperlocomotion in amphetamine pre-exposed rats: J.H. Kim & P. Vezina; Neuropharmacology 37, 189 (1998) Abstract
Pharmacological agents acting at subtypes of metabotropic glutamate receptors: D.D. Schoepp, et al.; Neuropharmacology 38, 1431 (1999), (Review) Abstract
 
 
ALX-550-054 Revised 28-Jan-05
(RS)-MCPG
Add to Clipboard
SYNONYMS (RS)-α-Methyl-4-carboxyphenylglycine
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Glutamate Receptors (Metabotropic) / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-550-054-M005   5 mg 80.00 USD Add To Cart
Product Specification
FORMULA: C10H11NO4
MW: 209.2
CAS NUMBER: 146669-29-6
PURITY: ≥97%
APPEARANCE: White solid.
SOLUBILITY: Soluble in dilute aqueous base. Insoluble in water, ethanol, DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: +20°C
HANDLING: Protect from light.

Product Specific Literature References
Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors: Z.I. Bashir, et al.; Nature 363, 347 (1993) Abstract
Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine: S.A. Eaton, et al.; Eur. J. Pharmacol. 244, 195 (1993) Abstract
Phenylglycine derivatives as antagonists of metabotropic glutamate receptors: J. Watkins & G. Collingridge; TIPS 15, 333 (1994), (Review) Abstract
Long-lasting enhancement of NMDA receptor-mediated synaptic transmission by metabotropic glutamate receptor activation: J.J. O'Connor, et al.; Nature 367, 557 (1994) Abstract
Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluR1: C. Joly, et al.; J. Neurosci. 15, 3970 (1995) Abstract
Agonists and antagonists for metabotropic glutamate receptors: P.L. Ornstein, et al.; Curr. Pharm. Design 1, 355 (1995), (Review)
(R,S)-alpha-methyl-4-carboxyphenylglycine (MCPG) fails to block long-term potentiation under urethane anaesthesia in vivo: S.J. Martin & R.G. Morris; Neuropharmacology 36, 1339 (1997) Abstract
Absolute configuration of (+)-alpha-methyl-4-carboxyphenylglycine (MCPG), a metabotropic glutamate receptor antagonist: C. Wilson, et al.; Acta. Crystallogr. C 53 ( Pt 7), 909 (1997) Abstract
The metabotropic glutamate receptor antagonist (RS)-MCPG produces hyperlocomotion in amphetamine pre-exposed rats: J.H. Kim & P. Vezina; Neuropharmacology 37, 189 (1998) Abstract
Inhibition of group I metabotropic glutamate receptors blocks spatial learning in rats: D. Balschun & W. Wetzel; Neurosci. Lett. 249, 41 (1998) Abstract
(+)-MCPG blocks induction of LTP in CA1 of rat hippocampus via agonist action at an mGluR group II receptor: N.A. Breakwell, et al.; J. Neurophysiol. 79, 1270 (1998) Abstract
Pharmacological a